Celldex Therapeutics (CLDX) Competitors $22.76 +0.14 (+0.62%) As of 01/16/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CLDX vs. IONS, ALKS, FOLD, LGND, GERN, MNKD, BCRX, DVAX, NVAX, and MYGNShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), Novavax (NVAX), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Ionis Pharmaceuticals Alkermes Amicus Therapeutics Ligand Pharmaceuticals Geron MannKind BioCryst Pharmaceuticals Dynavax Technologies Novavax Myriad Genetics Ionis Pharmaceuticals (NASDAQ:IONS) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking. Does the MarketBeat Community prefer IONS or CLDX? Ionis Pharmaceuticals received 77 more outperform votes than Celldex Therapeutics when rated by MarketBeat users. However, 75.21% of users gave Celldex Therapeutics an outperform vote while only 60.31% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIonis PharmaceuticalsOutperform Votes69660.31% Underperform Votes45839.69% Celldex TherapeuticsOutperform Votes61975.21% Underperform Votes20424.79% Is IONS or CLDX more profitable? Ionis Pharmaceuticals has a net margin of -44.58% compared to Celldex Therapeutics' net margin of -1,544.32%. Celldex Therapeutics' return on equity of -19.75% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ionis Pharmaceuticals-44.58% -88.98% -12.42% Celldex Therapeutics -1,544.32%-19.75%-18.86% Do insiders & institutionals believe in IONS or CLDX? 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer IONS or CLDX? Ionis Pharmaceuticals presently has a consensus target price of $60.65, indicating a potential upside of 87.88%. Celldex Therapeutics has a consensus target price of $62.25, indicating a potential upside of 173.51%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Ionis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ionis Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.68Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Does the media favor IONS or CLDX? In the previous week, Ionis Pharmaceuticals had 13 more articles in the media than Celldex Therapeutics. MarketBeat recorded 16 mentions for Ionis Pharmaceuticals and 3 mentions for Celldex Therapeutics. Ionis Pharmaceuticals' average media sentiment score of 0.38 beat Celldex Therapeutics' score of 0.08 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Celldex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, IONS or CLDX? Celldex Therapeutics has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIonis Pharmaceuticals$788M6.47-$366.29M-$2.44-13.23Celldex Therapeutics$6.88M219.46-$141.43M-$2.57-8.86 Which has more volatility and risk, IONS or CLDX? Ionis Pharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. SummaryIonis Pharmaceuticals and Celldex Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.51B$2.46B$5.20B$9.00BDividend YieldN/A0.68%5.13%4.04%P/E Ratio-8.866.2988.7617.21Price / Sales219.4692.461,272.6276.95Price / CashN/A16.6543.8336.01Price / Book2.513.395.344.79Net Income-$141.43M$31.95M$122.56M$224.98M7 Day Performance-6.53%-2.12%0.34%1.43%1 Month Performance-12.60%-1.82%1.12%2.02%1 Year Performance-42.68%-17.49%27.06%20.32% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics1.4016 of 5 stars$22.76+0.6%$62.25+173.5%-45.3%$1.51B$6.88M-8.86150Short Interest ↑IONSIonis Pharmaceuticals4.2227 of 5 stars$34.72+3.8%$60.65+74.7%-36.7%$5.48B$803.07M-14.23800Analyst ForecastALKSAlkermes4.4496 of 5 stars$28.25+0.6%$36.00+27.4%+7.2%$4.57B$1.51B14.492,100Short Interest ↓FOLDAmicus Therapeutics4.3337 of 5 stars$9.06+0.4%$16.88+86.3%-26.4%$2.71B$493.67M-26.65480Analyst ForecastLGNDLigand Pharmaceuticals4.9455 of 5 stars$105.27-1.0%$147.00+39.6%+56.3%$1.99B$152.42M41.9480Positive NewsGERNGeron3.5371 of 5 stars$2.94-7.3%$7.25+146.6%+48.2%$1.78B$29.48M-9.1970Analyst ForecastMNKDMannKind3.9076 of 5 stars$6.11+0.3%$9.07+48.5%+80.5%$1.69B$267.20M87.29400Short Interest ↓BCRXBioCryst Pharmaceuticals4.3303 of 5 stars$7.97+3.9%$15.17+90.3%+15.9%$1.65B$412.58M-13.07530Analyst ForecastShort Interest ↓DVAXDynavax Technologies4.5428 of 5 stars$12.55-0.6%$22.00+75.3%-12.6%$1.65B$260.81M96.55350Analyst ForecastAnalyst RevisionNews CoverageNVAXNovavax3.9743 of 5 stars$8.55-8.2%$17.83+108.6%+96.5%$1.37B$847.25M-3.781,990Gap DownMYGNMyriad Genetics4.058 of 5 stars$14.11-4.9%$24.27+72.0%-39.1%$1.28B$823.60M-10.852,700Analyst ForecastShort Interest ↑ Related Companies and Tools Related Companies Ionis Pharmaceuticals Alternatives Alkermes Alternatives Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives Geron Alternatives MannKind Alternatives BioCryst Pharmaceuticals Alternatives Dynavax Technologies Alternatives Novavax Alternatives Myriad Genetics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLDX) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDX Stock Alerts